Huahai Pharmaceutical to lift restrictions on targeted issuance shares

Zheshang Securities has completed its verification, confirming that 41,152,263 restricted shares issued by Zhejiang Huahai Pharmaceutical to specific investors will become eligible for public trading on September 25, 2025. This follows the company's receipt of approval from the China Securities Regulatory Commission on April 2, 2024, and the completion of share registration and lock-up procedures on March 25, 2025.

The shares, issued to 14 specific investors, were subject to a six-month lock-up period following the issuance. All shareholders have adhered to their lock-up commitments, and the release complies with relevant regulatory requirements. Post-issuance, the company's total share capital increased from 1,466,755,541 to 1,507,907,804 shares.

As of September 18, 2025, the company's total share capital stands at 1,497,251,412 shares. This adjustment considers the cancellation of 10,656,753 repurchased shares on June 16, 2025, and an increase of 361 shares from convertible bond conversions between March 25, 2025, and September 18, 2025.